This is an open access article under the terms of the Creat ive Commo ns Attri bution-NonCo mmercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. 5-year OS in patients with late TNM stage (P = .002). However, no significant association was observed between γδT17 cells and OS, regardless of the TNM stage. In conclusion, our findings suggest that enhanced Th17 and reduced Tc17 cells in the peripheral blood could be a significant predictor of a favorable prognosis for NSCLC patients.
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T (Th17), CD8
+ T (Tc17) and γδT cells (γδT17) were measured to determine their association with clinical outcomes and overall survival (OS) in NSCLC. All NSCLC patients were followed up until July 2018. Median follow-up time was 13.5 months (range 1-87 months). The 3-and 5-year survival rate was 27% and 19.6%, respectively. We found that Th17 cells and γδT17 cells were significantly increased, whereas Tc17 cells were markedly decreased in patients with NSCLC compared with those in NC. In addition, Th17 cells were significantly positively associated with T helper type 1 cells (Th1), whereas γδT17 cells were significantly negatively associated with γδT + interferon (IFN)-γ + cells. High percentages of peripheral Tc17 cells were significantly associated with favorable 5-year OS (P = .025), especially in patients with early TNM stage (P = .016). Furthermore, high percentages of peripheral Th17 cells were positively associated with favorable 5-year OS in patients with late TNM stage (P = .002). However, no significant association was observed between γδT17 cells and OS, regardless of the TNM stage. In conclusion, our findings suggest that enhanced Th17 and reduced Tc17 cells in the peripheral blood could be a significant predictor of a favorable prognosis for NSCLC patients.
| INTRODUC TI ON
Lung cancer is one of the most common human malignancies in the world and its mortality rate ranks first in cancer-related causes of death. 1 According to the histological features, lung cancer is divided into small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), and NSCLC accounts for approximately 80% or more.
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Although many novel treatment approaches have been developed for NSCLC, there are still no significant improvements in patient outcomes. 3 Therefore, finding prognostic biomarkers is important for choosing suitable therapeutic strategies for the individual patient to acquire maximum treatment benefits.
Interleukin-17 (IL-17) is a proinflammatory cytokine mainly secreted by Th17 cells, which are identified as a new subset of helper T cells that are different from T helper type 1 (Th1) and T helper type 2 (Th2) cells. 4, 5 In addition to Th17 cells, several other cell types are described as sources for IL-17, including CD8 + T cells, 6, 7 γδ T cells 8, 9 and innate lymphoid cells. 
| MATERIAL S AND ME THODS
| Patients and follow up
| Cell preparation and flow cytometry
Peripheral blood mononuclear cells of heparinized peripheral blood from the study subjects were isolated by Ficoll density gradient centrifugation (HAO YANG, Tianjin, China). Flow cytometry analysis of IL-17-producing cells was carried out as previously described.
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Briefly, 2 × 10 6 PBMC were stimulated with 50 ng/mL PMA and 500 ng/mL ionomycin in the presence of 10 μg/mL brefeldin A 
| Statistical analysis
All data are expressed as means ± SEM and were analyzed using GraphPad Prism 5 software for Windows (GraphPad Software).
Comparisons between groups were carried out by Student's t-test.
Correlations between variables were determined by Pearson coefficient analysis. Survival curves were carried out by using the Kaplan-Meier method and tested using the log-rank test using SPSS 18.0 for Windows (SPSS Inc.). P-values <.05 were considered statistically significant. 
| Decreased Tc17 cells, and increased Th17 cells and γδT17 cells in the peripheral blood of NSCLC patients
We then determined the frequencies of circulating Th17, Tc17, and γδT17 cells in patients with NSCLC. As shown in Figure 2 , the per- Figure 2F ). γδT17 cells were slightly increased in latestage patients compared to early-stage patients (P = .07, Figure 2I ).
| Interferon-γ and IL-17 double-positive T cells in the peripheral blood of NSCLC patients
As cells producing both IFN-γ and IL-17 have been identified in many tumors and are responsible for antitumor effects in tumor immunity, [19] [20] [21] we then evaluated the frequencies of IFN-γ and IL-17 double-positive T cells in patients with NSCLC. As shown in Figure 3 , the percentages of 
| Relationship between IL-17-producing T cells and their IFN-γ-producing partners in peripheral blood of NSCLC patients
To further explore the significance of IL-17-producing T cells in NSCLC, we analyzed the correlations between IL-17-producing T Figure 4E ). Moreover, we also observed a significant positive correlation between Th17 cells and Treg ( Figure 4G ), but not for Tc17 cells and γδT17 cells (Figure 4H,I ).
| Long-term prognostic significance of IL-17-producing T cells in NSCLC patients
We Figure S1D ).
| D ISCUSS I ON
It has been reported that T lymphocytes and their associated cytokines are abnormal in patients with cancer and are significantly involved in tumor development and progression. 24 In the present study, we found that levels of CD8 + T cells and Th1 cells in peripheral blood of patients with NSCLC were significantly decreased, whereas
Treg were increased, which were consistent with the previous findings. 25, 26 Nevertheless, no significant differences were observed between these cell populations and TNM stage; the reason may be Bars represent means ± SD. *P < .05; **P < .01; ***P < .001. IL, interleukin; TCR, T-cell receptor metastasis in mice. 32 As in the controversial role of IL-17 cytokine in the tumor, IL-17-producing T cells also showed a paradoxical role in tumor immunity. Adoptive transfer of tumor-specific Th17 cells prevented tumor development. 33 Th17-polarized cells were found to be more effective than Th1 cells in eliminating large established tumors, 34 and showed a stem cell-like property in tumor immunity.
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However, the infiltration of Th17 cells in the tumor site was associated with poor prognosis in hepatocellular carcinoma, 36 colorectal cancer, 37 pancreatic carcinoma, 38 as well as in thyroid tumor. as TNM staging, OS and DFS. 11, 12 In the current study, we found that high levels of peripheral Th17 and Tc17 cells were significantly associated with improved long-term OS in NSCLC, which was in accordance with previous studies in human esophageal squamous cell carcinoma (ESCC), 43 and in malignant pleural effusion. 44, 45 However, in the present study, there were no significant correlations between IL-17-producing cells and DFS. Although the discrepancy might be as a result of the limited sample of NSCLC patients, it has been reported that higher intratumoral IL-17A + cells were asso- In conclusion, our study showed for the first time that the peripheral Th17 and Tc17 cells were associated with a favorable prognosis in patients with NSCLC. Percentages of Th17 and Tc17 cells in the peripheral blood could be significant predictors of a favorable prognosis for NSCLC patients.
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F I G U R E 5
Kaplan-Meier analyses of the prognostic significance of interleukin (IL)-17-producing cells in non-small cell lung cancer (NSCLC) patients. Sixty-six NSCLC patients were divided into two groups based on their levels of IL-17-producing cells using cutoff values calculated by receiver operating characteristic curves (Th17: 1.15%; Tc17: 0.3%; γδT17: 2.33%). Five-year overall survival rates for NSCLC patients with a high and low level of (A) Th17, (B) Tc17, and (C) γδT17 cells are shown. (D-I) Five-year overall survival rates for NSCLC patients in stratified analyses by TNM stage. NSCLC patients with (D-F) early-stage (n = 17) or (G-I) late-stage (n = 49) cancer. Survival rates were determined using the Kaplan-Meier method and log-rank test. Vertical bars indicate censored cases
